Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it ...
Paolo Ghia, MD, PhD, discusses the CAPTIVATE trial in chronic lymphocytic leukemia/small lymphocytic lymphoma, and what ...
Hosted on MSN3mon
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting"Patients with treatment-naive CLL have several treatment options ... undetectable measurable residual disease (MRD), and OS. Undetectable MRD, measured in peripheral blood, was highest in ...
and clinical outcomes have been shown to be strongly associated with MRD levels measured by clonoSEQ in patients diagnosed with CLL, MM, B-ALL and DLBCL. For important information about the FDA ...
In chronic lymphocytic leukemia (CLL), the most prevalent lymphoid malignancy in western countries, patients have a median age at diagnosis of 72 years. In the last few years, there has been ...
and clinical outcomes have been shown to be strongly associated with MRD levels measured by clonoSEQ in patients diagnosed with CLL, MM, B-ALL and DLBCL. Adaptive Biotechnologies ("we” or "our”) is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback